SNDX – Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc.SNDX
$10.19Name : Syndax Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $876,822,976.00
EPSttm : -3.85
Syndax Pharmaceuticals, Inc.
$10.19
7.28%$0.8Float Short %
25.73
Margin Of Safety %
Put/Call OI Ratio
0.51
EPS Next Q Diff
0.08
EPS Last/This Y
0.02
EPS This/Next Y
1.19
Price
10.19
Target Price
35.75
Analyst Recom
1.23
Performance Q
-32.11
Relative Volume
0.99
Beta
0.78
Ticker: SNDX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | SNDX | 11.26 | 0.61 | 0.07 | 29594 |
| 2025-04-15 | SNDX | 11.34 | 0.60 | 0.00 | 29918 |
| 2025-04-16 | SNDX | 11.06 | 0.60 | 3.91 | 29922 |
| 2025-04-17 | SNDX | 11.57 | 0.53 | 0.01 | 28710 |
| 2025-04-18 | SNDX | 11.54 | 0.53 | 0.01 | 28710 |
| 2025-04-21 | SNDX | 11.95 | 0.63 | 0.00 | 24205 |
| 2025-04-22 | SNDX | 12.92 | 0.56 | 0.48 | 25868 |
| 2025-04-23 | SNDX | 13 | 0.58 | 0.00 | 30988 |
| 2025-04-24 | SNDX | 13.31 | 0.57 | 2.00 | 31483 |
| 2025-04-25 | SNDX | 13.33 | 0.56607809002736 | 1.8333333333333 | 31486 |
| 2025-04-28 | SNDX | 13.42 | 0.57093770230566 | 0.014925373134328 | 31546 |
| 2025-04-29 | SNDX | 13.69 | 0.57 | 3.62 | 31486 |
| 2025-04-30 | SNDX | 14.12 | 0.59 | 0.05 | 31731 |
| 2025-05-01 | SNDX | 13.74 | 0.58 | 0.00 | 31923 |
| 2025-05-02 | SNDX | 13.7 | 0.47 | 0.92 | 37255 |
| 2025-05-05 | SNDX | 13.55 | 0.48 | 0.01 | 37515 |
| 2025-05-06 | SNDX | 10.6 | 0.46 | 0.24 | 38655 |
| 2025-05-07 | SNDX | 9.97 | 0.51 | 0.04 | 37987 |
| 2025-05-08 | SNDX | 10.99 | 0.52 | 0.12 | 37507 |
| 2025-05-09 | SNDX | 10.69 | 0.50 | 0.38 | 39550 |
| 2025-05-12 | SNDX | 10.99 | 0.49 | 3.89 | 40735 |
| 2025-05-13 | SNDX | 10.19 | 0.51 | 0.44 | 41562 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | SNDX | 11.24 | -46.1 | 55.1 | -3.81 |
| 2025-04-15 | SNDX | 11.33 | -51.0 | 54.7 | -3.81 |
| 2025-04-16 | SNDX | 11.05 | -51.0 | 66.1 | -3.81 |
| 2025-04-17 | SNDX | 11.54 | -51.0 | 42.6 | -3.81 |
| 2025-04-18 | SNDX | 11.54 | -51.0 | 57.7 | -3.81 |
| 2025-04-21 | SNDX | 11.94 | -51.0 | 46.1 | -3.81 |
| 2025-04-22 | SNDX | 12.92 | -51.0 | 29.9 | -3.81 |
| 2025-04-23 | SNDX | 13.00 | -51.0 | 55.6 | -3.81 |
| 2025-04-24 | SNDX | 13.31 | -51.0 | 49.8 | -3.81 |
| 2025-04-25 | SNDX | 13.33 | -51.0 | 56.8 | -3.81 |
| 2025-04-28 | SNDX | 13.42 | -51.0 | 55.5 | -3.81 |
| 2025-04-29 | SNDX | 13.70 | -51.0 | 50.9 | -3.81 |
| 2025-04-30 | SNDX | 14.15 | -51.0 | 47.1 | -3.81 |
| 2025-05-01 | SNDX | 13.82 | -51.0 | 64.4 | -3.81 |
| 2025-05-02 | SNDX | 13.73 | -51.0 | 59.6 | -3.81 |
| 2025-05-05 | SNDX | 13.57 | -49.8 | 61.3 | -3.78 |
| 2025-05-06 | SNDX | 10.61 | -49.8 | 127.7 | -3.78 |
| 2025-05-07 | SNDX | 9.99 | -49.8 | 93.2 | -3.78 |
| 2025-05-08 | SNDX | 10.99 | -22.2 | -70.4 | -3.78 |
| 2025-05-09 | SNDX | 10.69 | -22.2 | 26.7 | -3.70 |
| 2025-05-12 | SNDX | 10.99 | -22.2 | -11.5 | -3.70 |
| 2025-05-13 | SNDX | 10.19 | -22.2 | 56.8 | -3.70 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | SNDX | -1.55 | 12.66 | 23.00 |
| 2025-04-15 | SNDX | -1.55 | 12.66 | 23.00 |
| 2025-04-16 | SNDX | -1.55 | 12.66 | 23.00 |
| 2025-04-17 | SNDX | -1.55 | 12.66 | 23.00 |
| 2025-04-18 | SNDX | -1.55 | 12.66 | 23.00 |
| 2025-04-21 | SNDX | -1.55 | 10.11 | 23.00 |
| 2025-04-22 | SNDX | -1.56 | 10.11 | 23.00 |
| 2025-04-23 | SNDX | -1.56 | 10.11 | 23.00 |
| 2025-04-24 | SNDX | -1.56 | 10.11 | 23.00 |
| 2025-04-25 | SNDX | -1.56 | 10.11 | 23.00 |
| 2025-04-28 | SNDX | -1.56 | 5.55 | 25.15 |
| 2025-04-29 | SNDX | -1.56 | 5.55 | 25.15 |
| 2025-04-30 | SNDX | -1.56 | 5.55 | 25.15 |
| 2025-05-01 | SNDX | -1.56 | 5.55 | 25.15 |
| 2025-05-02 | SNDX | -1.56 | 5.55 | 25.15 |
| 2025-05-05 | SNDX | -1.56 | -1.29 | 25.15 |
| 2025-05-06 | SNDX | -1.56 | -1.29 | 25.15 |
| 2025-05-07 | SNDX | -1.56 | -1.29 | 25.15 |
| 2025-05-08 | SNDX | -1.56 | -1.29 | 25.15 |
| 2025-05-09 | SNDX | -1.56 | -1.29 | 25.15 |
| 2025-05-12 | SNDX | -1.56 | 1.15 | 25.73 |
| 2025-05-13 | SNDX | -1.56 | 1.15 | 25.73 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.98
Avg. EPS Est. Current Quarter
-0.98
Avg. EPS Est. Next Quarter
-0.9
Insider Transactions
-1.56
Institutional Transactions
1.15
Beta
0.78
Average Sales Estimate Current Quarter
27
Average Sales Estimate Next Quarter
34
Fair Value
Quality Score
44
Growth Score
36
Sentiment Score
2
Actual DrawDown %
65.9
Max Drawdown 5-Year %
-65.5
Target Price
35.75
P/E
Forward P/E
PEG
P/S
20.06
P/B
4.08
P/Free Cash Flow
EPS
-3.87
Average EPS Est. Cur. Y
-3.7
EPS Next Y. (Est.)
-2.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-757.52
Relative Volume
0.99
Return on Equity vs Sector %
-177.7
Return on Equity vs Industry %
-160.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.09
EBIT Estimation
56.8
Syndax Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading